EIDHS Project Fact Sheets
The COVID-19 pandemic has given us a shared experience that shows how interconnected our lives are and how public health depends on each one of us. The World Health Organization (WHO) envisions a world where 1 billion more people are better protected and safe from health emergencies, no matter of where they live. It strives to increase equity in access to health care. To better address pandemic and epidemic risks, the WHO Hub for Pandemic and Epidemic Intelligence will strengthen intelligence specifically for pandemics and epidemics by striving for better data, better analytics, and better decisions. Embedded in WHO’s Health Emergencies Programme and building on consultations with hundreds of experts from different disciplines, sectors, and regions, it will leverage WHO’s unique convening power across nearly 200 countries to foster global solutions.
The COVID-19 pandemic has brought to the forefront the risk of major disease outbreaks and highlighted countries’ lack of preparedness to fight them. Pandemics are large disease outbreaks that affect several countries and pose major health, social, and economic risks. A quick-moving pathogen spreading across the globe has the potential to kill tens of millions of people, disrupt economies, and destabilize national security – just as COVID-19 has demonstrated. Climate change, urbanization, and the lack of water and sanitation are all factors that could contribute to fast-spreading, catastrophic outbreaks.
Antimicrobials are drugs – such as antibiotics – that kill or control disease-causing microbes. Antimicrobial resistance (AMR) occurs when microbes mutate or adapt in ways that enable them to withstand antimicrobials, rendering treatments ineffective. AMR is dramatically accelerated by the over-use and misuse of antimicrobials, including antibiotics, in people and animals.
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
Research to understand and treat some of the world’s most problematic diseases.
The National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) works to protect people at home and around the world from emerging and zoonotic infections ranging from A to Z—anthrax to Zika. We are living in an interconnected world where an outbreak of infectious disease is just a plane ride away.
Emerging Infectious Diseases, an open access, peer reviewed journal published monthly by the Centers for Disease Control and Prevention, promotes the recognition of new and reemerging infectious diseases around the world and improves the understanding of factors involved in disease emergence, prevention, and elimination. The journal is intended for professionals in infectious diseases and related sciences and welcomes contributions from infectious disease specialists in academia, industry, clinical practice, and public health, and from specialists in economics, social sciences, and other disciplines.
This tool has been designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). The tool is a shortened version of the 2012 Laboratory assessment tool that is widely used to assess national laboratory systems and the capacity of laboratories.
This is the first edition of guidanceon infection prevention and control (IPC) strategies for use when infection with a novel coronavirus(2019-nCoV) is suspected. It has been adapted from WHO’s Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV)infection,1based on current knowledge of the situation inChinaand other countries where cases were identifiedand experiences with severe acute respiratory syndrome (SARS)-CoV and MERS-CoV.2
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus identified in Wuhan, China(See: Surveillance case definitions for human infection with novel coronavirus, Interim guidance).